Travere Therapeutics Hits New 52-Week High of $45.43

Travere Therapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 45.43 on May 4, 2026. This achievement underscores the company's remarkable performance over the past year, with a staggering increase of 517.74%, significantly outpacing the S&P 500's growth of 26.63% during the same period. The company's market capitalization stands at USD 2,586 million, reflecting its position within the small-cap category. Despite being loss-making, Travere Therapeutics has shown resilience with a notable growth in net sales of 19.03%. The company has reported positive results for three consecutive quarters, highlighting its operational strength. Key financial metrics include an operating cash flow of USD 37.79 million and a net profit of USD 3.72 million for the half-year period. Additionally, the return on capital employed (ROCE) stands at -57.8%. With a price-to-book ratio of 22.52 and a debt-to-equity ratio of -0.05, Travere Therapeutics continues to navigate the competitive landscape of the biotechnology industry effectively.